The General Accountability Office (GAO) should press the FDA to stop being passive in its oversight of device safety and instead take a more bold and active role, according to several academicians who collaborated on an opinion piece in the peer-reviewed healthcare journal Health Affairs.
Source: Drug Industry Daily